<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03813121</url>
  </required_header>
  <id_info>
    <org_study_id>229077</org_study_id>
    <nct_id>NCT03813121</nct_id>
  </id_info>
  <brief_title>The Effects of Sedatives on Tobacco Use Disorder</brief_title>
  <acronym>SED-TUD</acronym>
  <official_title>The Effects of Sedatives on Tobacco Use Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Arkansas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Arkansas</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This proposal will obtain preliminary data on the effect of a single sub-anesthetic dose of a&#xD;
      sedative on cigarette craving and smoking behavior as well as measuring tolerability and&#xD;
      acceptability.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2019</start_date>
  <completion_date type="Anticipated">February 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>single-blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>side effects</measure>
    <time_frame>about 1 week post infusion</time_frame>
    <description>drug side effects scale: severity scale from 1 (not at all) to 7 (extremely) for symptoms of nausea, dizziness, sleepiness, strange thoughts, hallucinations, confusion, anxiousness, and headache. Mean subscales scored separately. Higher scores indicate worse outcome (range 1 to 7).</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Tobacco Use Disorder</condition>
  <arm_group>
    <arm_group_label>midazolam intravenous infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single midazolam infusion (0.02 mg/kg over 20 minutes)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo intravenous infusion</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>single placebo infusion (saline over 20 minutes)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ketamine intravenous infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single ketamine infusion (0.5 mg/kg over 20 minutes)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>midazolam intravenous infusion</intervention_name>
    <description>Participants will receive a single drug infusion</description>
    <arm_group_label>midazolam intravenous infusion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo intravenous infusion</intervention_name>
    <description>Participants will receive a single placebo infusion</description>
    <arm_group_label>placebo intravenous infusion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ketamine intravenous infusion</intervention_name>
    <description>Participants will receive a single drug infusion</description>
    <arm_group_label>ketamine intravenous infusion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  smoke at least 5 cigarettes per day&#xD;
&#xD;
          -  smoked at least 2 years&#xD;
&#xD;
          -  negative urine drug screen for psychoactive drugs and negative breath alcohol&#xD;
             concentration&#xD;
&#xD;
          -  live in Little Rock AR or surrounding area&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  unstable or stable medical condition that would interact with study medication or&#xD;
             participation&#xD;
&#xD;
          -  serious head trauma or neurological disorder&#xD;
&#xD;
          -  hypertension, abnormal ECG or metabolic blood results&#xD;
&#xD;
          -  meet criteria for psychosis, schizophrenia, major depressive disorder, or bipolar&#xD;
             disorder&#xD;
&#xD;
          -  use of psychoactive drugs or medications&#xD;
&#xD;
          -  BMI &gt; 40&#xD;
&#xD;
          -  among women, pregnancy or breastfeeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Merideth Addicott, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Arkansas</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Merideth Addicott, PhD</last_name>
    <phone>5015268436</phone>
    <email>MAddicott@uams.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Arkansas for Medical Sciences</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Merideth Addicott, PhD</last_name>
      <phone>501-526-8436</phone>
      <email>maddicott@uams.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>January 18, 2019</study_first_submitted>
  <study_first_submitted_qc>January 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 23, 2019</study_first_posted>
  <last_update_submitted>June 7, 2021</last_update_submitted>
  <last_update_submitted_qc>June 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tobacco Use Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Midazolam</mesh_term>
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

